Onego Bio, a Finnish plant-based egg producer, has raised USD 40 million in Series A funding led by NordicNinja, with participation from Tesi, EIT Food, Agronomics, Maki.vc, and Holdix and Turret, among others. This round also included USD 10 million in non-dilutive funding from Business Finland.
The new funding will be used to support its North American commercialization efforts, including scaling production capacity and increasing the headcount of the US commercial team. Further, the company will partner with co-manufacturers to expedite its market entry process.
Analyst QuickTake: Onego Bio uses a combination of precision fermentation and cellular agriculture to develop Bioalbumen (animal-free egg protein). The company is on track to commercialize Bioalbumen in the US with self-affirmed GRAS status and a "no objections letter" from the FDA expected soon.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.